AI USED TO AUTOMATE ASSESSMENTS
Scotland currently has the highest incidence of the ‘asbestos cancer’ Mesothelioma in the world: a reflection of the historical use of asbestos in many United Kingdom industries, including shipbuilding and construction.
M
esothelioma is a type of cancer that develops in the lining that covers the outer surface of some of the body's
organs. It's usually linked to asbestos exposure.
More than 2,600 people are diagnosed with the condition each year in the United Kingdom, with most cases are diagnosed in people aged 60 to 80. Men tend to be affected more commonly than women.
Now, patients receiving treatment for Mesothelioma, are being assessed with Artificial Intelligence (AI) as part of a prototype imaging system, which could revolutionise the way people with the disease are cared for.
A team from NHS Greater Glasgow and Clyde Research and Innovation worked alongside AI company, Canon Medical, and University of Glasgow clinical researchers based at Queen Elizabeth University Hospital.
The team created a prototype AI system able to automatically find and measure Mesothelioma on
36
scottishpharmacist.com
CT scans, which are used to assess patient’s response to drug treatments like chemotherapy.
The AI was trained by showing it over 100 CT scans, on which an expert clinician had drawn around all areas of the tumour – showing the AI what to look for. The trained AI was then shown a new set of scans and was able to find and measure the tumour extremely accurately, without any human input.
The tool, which could revolutionise the fight against cancer, intentionally focused on Mesothelioma given its prominence in Scotland. The successful results of the project will provide a strong foundation for similar tools to be developed in the assessment of other cancers.
‘To our knowledge,’ said Professor Kevin Blyth, Honorary Consultant Respiratory Physician at Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde and Professor of Respiratory Medicine in the University of Glasgow, ‘this study is world-leading in its
successful use of AI to assess treatment response in Mesothelioma. Using external data sets to validate our results, we have shown that tumours can be accurately measured by AI, giving us a new tool that will help us make better decisions for patients on treatment and reducing barriers to development of new treatments in clinical trials.’
New service launched Last year, to mark Action Mesothelioma Day, a new approach was launched in Scotland to optimise care for patients affected by the disease. The Scottish Mesothelioma Network comprises healthcare professionals from across Scotland, who collaborate to share best practice and provide high-quality clinical care, information and support to all patients, wherever they live in Scotland.
For more information, visit
scottishmesotheliomanetwork.scot.nhs.uk/
THE AI WAS TRAINED BY SHOWING IT OVER 100 CT SCANS, ON WHICH AN EXPERT CLINICIAN HAD DRAWN AROUND ALL AREAS OF THE TUMOUR – SHOWING THE AI WHAT TO LOOK FOR
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
